These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11888329)

  • 41. Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules.
    Mittapalli RK; Manda VK; Adkins CE; Geldenhuys WJ; Lockman PR
    Ther Deliv; 2010 Dec; 1(6):775-84. PubMed ID: 22834013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.
    Ghosh C; Puvenna V; Gonzalez-Martinez J; Janigro D; Marchi N
    Curr Drug Metab; 2011 Oct; 12(8):742-9. PubMed ID: 21568937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.
    Kibathi LW; Bae S; Penzak SR; Kumar P
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):619-635. PubMed ID: 29858835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.
    Bertrand L; Nair M; Toborek M
    Curr Pharm Des; 2016; 22(35):5477-5486. PubMed ID: 27464720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
    Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
    Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carrier-mediated or specialized transport of drugs across the blood-brain barrier.
    Tsuji A; Tamai I
    Adv Drug Deliv Rev; 1999 Apr; 36(2-3):277-290. PubMed ID: 10837720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system.
    Begley DJ
    J Pharm Pharmacol; 1996 Feb; 48(2):136-46. PubMed ID: 8935161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CNS as a target for peptides and peptide-based drugs.
    Banks WA
    Expert Opin Drug Deliv; 2006 Nov; 3(6):707-12. PubMed ID: 17076593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of passive drug entry into the central nervous system.
    Habgood MD; Begley DJ; Abbott NJ
    Cell Mol Neurobiol; 2000 Apr; 20(2):231-53. PubMed ID: 10696512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microdialysis in the study of drug transporters in the CNS.
    Sawchuk RJ; Elmquist WF
    Adv Drug Deliv Rev; 2000 Dec; 45(2-3):295-307. PubMed ID: 11108981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier.
    Mikitsh JL; Chacko AM
    Perspect Medicin Chem; 2014; 6():11-24. PubMed ID: 24963272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system.
    Sawchuk RJ; Yang Z
    Adv Drug Deliv Rev; 1999 Oct; 39(1-3):5-31. PubMed ID: 10837765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The aetiology of neurological complications of organic acidaemias--a role for the blood-brain barrier.
    Kölker S; Sauer SW; Surtees RA; Leonard JV
    J Inherit Metab Dis; 2006 Dec; 29(6):701-4; discussion 705-6. PubMed ID: 17041745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peptide prodrugs for the treatment of CNS disorders: a perspective for new drugs.
    Chin CM; Chiba DE; Machado MG; Vizioli Ede O; Santos JL
    Curr Med Chem; 2014; 21(23):2599-609. PubMed ID: 24533804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1).
    Kusuhara H; Sugiyama Y
    Drug Discov Today; 2001 Feb; 6(3):150-156. PubMed ID: 11165188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Molecular Mechanism Underlying the Function and Disintegration of the Central Nerve System Barrier Unraveled by Proteo-typing of Membrane Proteins].
    Terasaki T
    Brain Nerve; 2021 Jan; 73(1):59-78. PubMed ID: 33361514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
    Gu X; Zhang H; Jiao M; Han B; Zhang Z; Li J; Zhang Q
    Eur J Med Chem; 2022 Feb; 229():114090. PubMed ID: 34992037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug-resistant epilepsy.
    Vázquez M; Fagiolino P
    Epilepsia Open; 2022 Aug; 7 Suppl 1(Suppl 1):S47-S58. PubMed ID: 34560816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The brain in flux: Genetic, physiologic, and therapeutic perspectives on transporters in the CNS.
    Hewett SJ; Prado VF; Robinson MB
    Neurochem Int; 2021 Mar; 144():104980. PubMed ID: 33524471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2).
    Kusuhara H; Sugiyama Y
    Drug Discov Today; 2001 Feb; 6(4):206-212. PubMed ID: 11173268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.